Literature DB >> 8232539

Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice.

R Tisch1, X D Yang, S M Singer, R S Liblau, L Fugger, H O McDevitt.   

Abstract

Knowing the autoantigen target(s) in an organ-specific autoimmune disease is essential to understanding its pathogenesis. Insulin-dependent diabetes mellitus (IDDM) is an autoimmune disease characterized by lymphocytic infiltration of the islets of Langerhans (insulitis) and destruction of insulin-secreting pancreatic beta-cells. Several beta-cell proteins have been identified as autoantigens, but their importance in the diabetogenic process is not known. The non-obese diabetic (NOD) mouse is a murine model for spontaneous IDDM. Here we determine the temporal sequence of T-cell and antibody responses in NOD mice to a panel of five murine beta-cell antigens and find that antibody and T-cell responses specific for the two isoforms of glutamic acid decarboxylase (GAD) are first detected in 4-week-old NOD mice. This GAD-specific reactivity coincides with the earliest detectable response to an islet extract, and with the onset of insulitis. Furthermore, NOD mice receiving intrathymic injections of GAD65 exhibit markedly reduced T-cell proliferative responses to GAD and to the rest of the panel, in addition to remaining free of diabetes. These results indicate that the spontaneous response to beta-cell antigens arises very early in life and that the anti-GAD immune response has a critical role in the disease process during this period.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8232539     DOI: 10.1038/366072a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  232 in total

Review 1.  Immunotherapy of immune-mediated diabetes. Present and future.

Authors:  N Maclaren
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 2.  New concepts of the etiopathogenesis and treatment of insulin-dependent diabetes mellitus.

Authors:  J F Bach
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 3.  Immune mechanisms that regulate susceptibility to autoimmune type I diabetes.

Authors:  B Singh; T L Delovitch
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

4.  Induction of hyporesponsiveness to intact foreign protein via retroviral-mediated gene expression: the IgG scaffold is important for induction and maintenance of immune hyporesponsiveness.

Authors:  Y Kang; M Melo; E Deng; R Tisch; M El-Amine; D W Scott
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

Review 5.  Etiology of autoimmunity.

Authors:  N Sarvetnick
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

Review 6.  Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire?

Authors:  M Peakman; C M Dayan
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

7.  Analysis of structure and function relationships of an autoantigenic peptide of insulin bound to H-2K(d) that stimulates CD8 T cells in insulin-dependent diabetes mellitus.

Authors:  F Susan Wong; Antonis K Moustakas; Li Wen; George K Papadopoulos; Charles A Janeway
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-09       Impact factor: 11.205

8.  Identification of immunodominant T cell epitopes of human glutamic acid decarboxylase 65 by using HLA-DR(alpha1*0101,beta1*0401) transgenic mice.

Authors:  S D Patel; A P Cope; M Congia; T T Chen; E Kim; L Fugger; D Wherrett; G Sonderstrup-McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

9.  A diabetes-associated T-cell autoantigen maps to a telomeric locus on mouse chromosome 6.

Authors:  A Dallas-Pedretti; M McDuffie; K Haskins
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

Review 10.  The role of infections in autoimmune disease.

Authors:  A M Ercolini; S D Miller
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.